A Spinal Cord Injury Drug May Be Repurposed to Treat…

A Spinal Cord Injury Drug May Be Repurposed to Treat Alzheimer's, and It's Already Passed Human Safety Trials Most approved Alzheimer's treatments have focused almost entirely on one target, amyloid beta, the sticky protein buildup long associated with the disease. The results have been modest at best. A new study from King's College London suggests a genuinely different approach, one that tackles multiple disease processes at once, and could reach patients faster than a typical new drug. KCL-286 was originally developed for spinal cord injury, not Alzheimer's. It has already completed Phase 1 human safety and tolerability trials for that original purpose. This matters enormously, since drug development from scratch typically takes many years just to reach this stage. Researchers believe this existing safety data could dramatically shorten the path toward Alzheimer's specific clinical trials. The same King's College London team had